• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶介导药物处置模型的近似值及模型参数的可识别性。

Approximations of the target-mediated drug disposition model and identifiability of model parameters.

作者信息

Gibiansky Leonid, Gibiansky Ekaterina, Kakkar Tarundeep, Ma Peiming

机构信息

QuantPharm LLC, North Potomac, MD, USA.

出版信息

J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91. doi: 10.1007/s10928-008-9102-8. Epub 2008 Nov 13.

DOI:10.1007/s10928-008-9102-8
PMID:19005743
Abstract

Models for drugs exhibiting target-mediated drug disposition (TMDD) play an important role in the investigation of biological products (Mager and Jusko 2001). These models are often overparameterized and difficult to converge. A simpler quasi-equilibrium (QE) approximation of the general model has been suggested (Mager and Krzyzanski 2005), but even this simpler form can be overparameterized when, for example, drug target level is not available. This work (a) introduces quasi-steady-state (QSS) and Michaelis-Menten (MM) approximations of the TMDD model, (b) derives the relationships between the parameters of the TMDD, QE, QSS and MM models, (c) investigates the parameter ranges where the simplified approximations are equivalent to the TMDD model, (d) proposes an algorithm for establishing identifiability of these models, and (e) tests this algorithm on simulated datasets. The proposed QSS approximation is more general than the QE approximation: it degenerates into the QE approximation when the internalization rate of the drug-target complex is much smaller than its dissociation rate. The proposed identifiability analysis algorithm may be applied to provide justification for use of simplified approximations, avoiding use of incorrect parameter estimates of over-parameterized TMDD models while simultaneously saving time and resources required for the pharmacokinetics analysis of drugs with TMDD. The utility of the derived approximations and of the identifiability algorithm was demonstrated on the examples of the simulated data sets. The simulation examples indicated that the QSS model may be preferable to the QE model when the internalization rate of the drug-target complex significantly exceeds its dissociation rate. The MM approximation may be adequate when the drug concentration significantly exceeds the target concentrations or when the target occupancy is close to 100%.

摘要

表现出靶点介导药物处置(TMDD)的药物模型在生物制品研究中发挥着重要作用(Mager和Jusko,2001年)。这些模型往往参数过多且难以收敛。有人提出了一种更简单的通用模型准平衡(QE)近似法(Mager和Krzyzanski,2005年),但即使是这种更简单的形式,在例如药物靶点水平不可用时也可能参数过多。这项工作:(a)引入了TMDD模型的准稳态(QSS)和米氏(MM)近似法;(b)推导了TMDD、QE、QSS和MM模型参数之间的关系;(c)研究了简化近似法与TMDD模型等效的参数范围;(d)提出了一种确定这些模型可识别性的算法;(e)在模拟数据集上测试了该算法。所提出的QSS近似法比QE近似法更具通用性:当药物 - 靶点复合物的内化速率远小于其解离速率时,它会退化为QE近似法。所提出的可识别性分析算法可用于为简化近似法的使用提供依据,避免使用参数过多的TMDD模型的错误参数估计,同时节省具有TMDD的药物药代动力学分析所需的时间和资源。在模拟数据集的示例中证明了所推导近似法和可识别性算法的实用性。模拟示例表明,当药物 - 靶点复合物的内化速率显著超过其解离速率时,QSS模型可能比QE模型更可取。当药物浓度显著超过靶点浓度或靶点占有率接近100%时,MM近似法可能是合适的。

相似文献

1
Approximations of the target-mediated drug disposition model and identifiability of model parameters.靶介导药物处置模型的近似值及模型参数的可识别性。
J Pharmacokinet Pharmacodyn. 2008 Oct;35(5):573-91. doi: 10.1007/s10928-008-9102-8. Epub 2008 Nov 13.
2
Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.具有两个结合位点且其中一个结合位点与靶点结合的药物的靶点介导药物处置模型。
J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):463-475. doi: 10.1007/s10928-017-9533-1. Epub 2017 Jul 19.
3
Target-mediated drug disposition model for drugs that bind to more than one target.针对与多个靶点结合的药物的基于靶点的药物处置模型。
J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):323-46. doi: 10.1007/s10928-010-9163-3. Epub 2010 Jul 29.
4
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.靶向介导的药物处置模型:模型参数的近似值、可识别性及其在生物药剂学群体药代动力学-药效学建模中的应用。
Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12. doi: 10.1517/17425250902992901.
5
Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.药物-药物相互作用下的靶点介导药物处置,第一部分:不同制剂中的单一药物情况
J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):17-26. doi: 10.1007/s10928-016-9501-1. Epub 2017 Jan 10.
6
Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.具有 N > 2 个结合位点且与具有一个结合位点的靶标结合的药物的靶标介导的药物处置模型。
J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):703-720. doi: 10.1007/s10928-024-09917-8. Epub 2024 Apr 19.
7
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.MPBPK-TMDD 模型用于单克隆抗体:替代模型、比较和可识别性问题。
J Pharmacokinet Pharmacodyn. 2018 Dec;45(6):787-802. doi: 10.1007/s10928-018-9608-7. Epub 2018 Nov 10.
8
Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.基于靶器官介导药物处置模型的理论考虑:简化与近似。
Pharm Res. 2012 Mar;29(3):866-82. doi: 10.1007/s11095-011-0615-2. Epub 2011 Dec 1.
9
A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations.目标介导药物处置模型及其近似值的先验可识别性
AAPS J. 2015 Sep;17(5):1280-4. doi: 10.1208/s12248-015-9795-8. Epub 2015 Jun 16.
10
Target mediated drug disposition with drug-drug interaction, Part II: competitive and uncompetitive cases.药物-药物相互作用下的靶点介导药物处置,第二部分:竞争性和非竞争性情况。
J Pharmacokinet Pharmacodyn. 2017 Feb;44(1):27-42. doi: 10.1007/s10928-016-9502-0. Epub 2017 Jan 10.

引用本文的文献

1
Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab.群体药代动力学/药效学分析证实SB16与参比地诺单抗具有生物相似性。
Front Pharmacol. 2025 Aug 19;16:1631034. doi: 10.3389/fphar.2025.1631034. eCollection 2025.
2
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics.免疫球蛋白G受体(FcγR),除了靶抗原和新生儿Fc受体(FcRn)外,还影响利妥昔单抗的药代动力学。
Clin Pharmacokinet. 2025 Aug 14. doi: 10.1007/s40262-025-01549-6.
3
Population Pharmacokinetics and Pharmacodynamics Modeling for the Use of Recaticimab in Healthy Volunteers and Patients with Hypercholesterolemia.

本文引用的文献

1
A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.一种基于机制的奥马珠单抗群体药代动力学和药效学结合模型。
Br J Clin Pharmacol. 2007 May;63(5):548-61. doi: 10.1111/j.1365-2125.2006.02803.x. Epub 2006 Nov 10.
2
Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition.用于表现出靶点介导药物处置的药物的准平衡药代动力学模型。
Pharm Res. 2005 Oct;22(10):1589-96. doi: 10.1007/s11095-005-6650-0. Epub 2005 Sep 22.
3
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.
瑞卡奇单抗在健康志愿者和高胆固醇血症患者中应用的群体药代动力学和药效学建模
Clin Pharmacokinet. 2025 Jun 30. doi: 10.1007/s40262-025-01512-5.
4
Target-Mediated Drug Disposition (TMDD) Revisited: High Versus Low-Affinity Approximations of the TMDD Model.再探靶点介导的药物处置(TMDD):TMDD模型的高亲和力与低亲和力近似值
CPT Pharmacometrics Syst Pharmacol. 2025 Jul;14(7):1262-1272. doi: 10.1002/psp4.70048. Epub 2025 May 27.
5
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.皮下注射依泊妥单抗治疗复发或难治性B细胞非霍奇金淋巴瘤后的群体药代动力学
Clin Pharmacokinet. 2025 Jan;64(1):127-141. doi: 10.1007/s40262-024-01464-2. Epub 2024 Dec 21.
6
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY (M6495) using the neo-epitope ARGS as a biomarker.使用新表位ARGS作为生物标志物的抗ADAMTS-5纳米抗体(M6495)的转化药代动力学和药效学建模。
J Pharmacokinet Pharmacodyn. 2024 Dec 20;52(1):8. doi: 10.1007/s10928-024-09958-z.
7
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod.抗FcRn片段抗体艾加莫德的转化性群体靶向结合模型
J Pharmacokinet Pharmacodyn. 2024 Dec 5;52(1):2. doi: 10.1007/s10928-024-09952-5.
8
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies.长效 PCSK9 单克隆抗体昂戈利昔单抗的临床药代动力学和药效学:在健康受试者和高胆固醇血症患者中的随机、双盲、安慰剂对照的 Ia 期和 Ib/II 期研究。
Clin Transl Sci. 2024 Nov;17(11):e70061. doi: 10.1111/cts.70061.
9
Pharmacometrics-Enhanced Bayesian Borrowing for Pediatric Extrapolation - A Case Study of the DINAMO Trial.药代动力学增强的贝叶斯借用方法用于儿科外推——以DINAMO试验为例
Ther Innov Regul Sci. 2025 Jan;59(1):112-123. doi: 10.1007/s43441-024-00707-5. Epub 2024 Oct 7.
10
Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.基于生理学的药代动力学模型与相对转录组学相结合,以评估阿尼鲁单抗的组织分布和受体占有率。
CPT Pharmacometrics Syst Pharmacol. 2025 Jan;14(1):105-117. doi: 10.1002/psp4.13245. Epub 2024 Oct 3.
表现出靶点介导药物处置的药物的一般药代动力学模型。
J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32. doi: 10.1023/a:1014414520282.